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Transforming growth factor-β1( T G F - β1) is a polypeptide member of the transforming growth factor β superfamily of cytokines.
It is a secreted protein that performs many cellular functions including control of cell growth, cell proliferation, cell diﬀerentiation
and apoptosis. In the cardiovascular system, TGF-β1 plays pivotal roles in the pathogenesis of hypertension, restenosis after
percutaneouscoronaryintervention,atherosclerosis,cardiachypertrophyandheartfailure.Inaddition,TGF-β1hasbeenshownto
beincreasedinadiposetissueofobesesubjectswithinsulinresistance.Furthermore,TGF-β1isapotentinitiatorofproliferationof
renal mesangial cells leading to chronic kidney disease. Some currently available agents can manipulate TGF-β1 expression leading
to amelioration of cardiovascular diseases. Thus, an understanding of interactions between chronic kidney disease and metabolic
syndrome and the development of cardiovascular diseases is an important issue, and attention should be given to TGF-β1a sa
crucial factor for regulation and modulation of those pathological conditions.
1.Introduction
Transforming growth factor-β (TGF-β)i sap o l y p e p t i d e
member of the TGF-β superfamily of cytokines. The TGF-
β superfamily consists of TGF-β, activins, inhibins, growth
diﬀerentiation factors, and bone morphogenetic proteins
(BMPs). The TGF-β superfamily proteins share common
sequences and motifs to exert their various biological
actions, including cell growth, diﬀerentiation, proliferation,
migration, adhesion, apoptosis, and extracellular matrix
(ECM) production (Figure 1)[ 1–4]. Experimental studies
on TGF-β signaling pathway manipulation have conﬁrmed
crucial roles of TGF-β in the process of development and/or
regressionofmalignanttumors,autoimmunediseases,organ
ﬁbrotic changes, kidney diseases, and cardiovascular dis-
eases (CVD) [4]. TGF-β exists in three known subtypes
in humans, TGF-β1, TGF-β2, and TGF-β3. Since TGF-
β1 is present in endothelial cells, vascular smooth muscle
cells (VSMCs), myoﬁbroblasts, macrophages, and other
hematopoietic cells, it is recognized as the most pivotal
TGF-β isoform for the cardiovascular system [5]. TGF-β1
is synthesized and secreted into the extracellular matrix as
an inactive precursor protein consisting of a signal peptide,
latency-associated peptide (LAP) domain, and mature TGF-
β1. Activation of TGF-β1 is involved in proteolytic cleavage
of LAP, and TGF-β1 is activated by thrombospondin-1, plas-
min, acidic microenvironments, matrix metalloproteinases
(MMPs) such as MMP-2 and -9, and β6 integrin [5–7]. In
VSMCs, angiotensin II (Ang II) enhances TGF-β1m R N A
expressionbytranscriptionalandposttranscriptionalactions
and accelerates its conversion to the biologically active form
[8].2 Cardiology Research and Practice
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Figure 1: Schematic diagram of TGF-β superfamily signaling pathway. TGF-β is produced as a latent protein that is activated by various
factors including plasmin, MMPs, and Tsp-1. Active form of TGF-β binds to its receptors and induces Smad2/3 phosphorylation, and
BMPs induce Smad1/5/8 phosporylation. Activated R-Smads, form heteromeric complexes with Smad4 and regulate the expression of target
genes of TGF-β such as ﬁbronectin, collagen type I, PAI-1 and MMP-2 in the nucleus. TGF-β: transforming growth factor-β,L A P :l a t e n c y -
associated peptide, MMPs: metalloproteinases, Tsp-1: thrombospondin-1 and BMP: bone morphogenetic protein.
Previous studies has shown that TGF-β1a c t i v a t i o ni s
closely associated with the development of cardiovascular
diseases, including hypertension [9], cardiac hypertrophy
[10] and cardiac ﬁbrosis [11] leading to heart failure as
well as restenosis after coronary intervention [12]a n d
atherosclerosis [13, 14]. Moreover, TGF-β1 is known to
induce progression of experimental renal disorders, and it
has been shown that there are associations between serum
level of TGF-β1 and risk factors for progression of clinically
relevant renal disorders in humans [15]. Visceral fat obesity
with insulin resistance has been considered to play a central
role in the development of metabolic syndrome (MetS)
leading to an increase in the incidence of cardiovascular
events, and recent studies have shown a possible interaction
between TGF-β1 and visceral fat obesity [16].
There are some elaborate review articles concerning
associations between TGF-β1 and CVD [4, 17–20]; however,
in this review, we focus on the importance of TGF-β1f o r ,
linking the pathologic processes of CVD, renal insuﬃciency,
and MetS.
2.Mechanism of TGF-β Superfamily Signaling
Pathway
TGF-β superfamily ligands exert their biological eﬀects via
binding to high-aﬃnity cell surface receptors, including type
Ia n dt y p eI IT G F - β superfamily receptors. Seven type I
receptors (activin-like kinase (ALK) 1–7) and ﬁve type II
receptors are known to be present in mammals [21–23].
Type II receptors are constitutively active serine/threonine
kinases, with ligand binding resulting in conformational
changes that induce recruitment and complex formation
with an appropriate type I receptor (ALK1-7) [24], and the
type II receptor then phosphorylates the type I receptor
in the glycine/serine-rich domain. The activated type I
receptors mediate their cellular actions through interaction
and phosphorylation of Smad proteins, which are often in
complexwithotherSmads,andactastranscriptionfactorsto
regulate the expression of various target genes [1, 25]. Based
on their function, Smads proteins have been classiﬁed into
threegroups:receptor-activatedSmads(R-Smads),including
Smad1, Smad2, Smad3, Smad5, and Smad8, the comediator
Smad Smad4, and inhibitory Smads, Smad6, and Smad7.
Smad2 and Smad3 are speciﬁc mediators of TGF-β/activin
pathways, whereas Smad1, Smad5, and Smad8 are involved
in BMP signaling (Figure 1)[ 1, 2].
3. TGF-β1andCardiovascularDiseases
SinceclinicalandexperimentalstudieshaveshownthatTGF-
β1 is involved in the development of CVD, it is absolutely
imperative to understand the biological actions of TGF-β1i n
the cardiovascular system.Cardiology Research and Practice 3
3.1. Role of TGF-β1 in the Development of Vascular Diseases.
In experimental models, targeting disruption of the TGF-
β1 gene prevents neointima hyperplasia and constrictive
remodeling after vascular injury such as angioplasty [12,
26, 27]. In diseased vessels such as arteries in patients with
atherosclerosis, type I receptor expression is enhanced and
TGF-β1 stimulates extracellular matrix (ECM) production
and can promote early fatty streak lesion formation [28, 29].
In addition, it has been reported that TGF-β1r e d u c e sc o l -
lagenase production and accelerates the expression of tissue
inhibitors of MMPs, resulting in overall inhibition of ECM
degradationandleadingtoexcessivematrixaccumulation[6,
30]. In addition, TGF-β1 can stimulate VSMCs to produce
collagen synthesis; however, TGF-β1 has been shown to be
involved in both positive and negative plaque stabilization
[31–33]. TGF-β1 also acts as a mediator of vascular ﬁbrosis
induced by several cardiovascular stress factors that are
involved in CVD, including mechanical stress, angiotensin II
(AngII),highglucose,andadvancedglycationproducts[34–
36].
3.2. Role of TGF-β1 in the Development of Cardiac Diseases.
Tissue levels of TGF-β1 are markedly increased in the
hypertrophicmyocardiumaftercardiacstressloadingsuchas
A n gI Ie x c e s s[ 37, 38]. Furthermore, it has been reported that
TGF-β1 stimulation alters the program of diﬀerentiation-
relatedgeneexpressioninisolatedcardiacmyocytes,promot-
ingthesynthesisoffetalcontractileproteins,characteristicof
pressure-overloadhypertrophy[39].OverexpressionofTGF-
β1 in transgenic mice results in cardiac hypertrophy that is
characterized by both interstitial ﬁbrosis and hypertrophic
growth of cardiomyocytes [40]. Local production of TGF-β1
in the hypertrophic myocardium and the link between the
renin-angiotensin-aldosterone system and TGF-β1 signaling
pathway are involved in the hypertrophic response. Since
it is well known that Ang II enhances TGF-β1 expression
and TGF-β1-Smad signaling pathways, cardiac remodeling,
including cardiac hypertrophy, and cardiac ﬁbrosis, through
activation of TGF-β1 is closely associated with excess of Ang
II [4].
On the other hand, Shultz et al. showed that the
cardiomyocyte cross sectional area was markedly increased
in Ang II-treated wild-type (WT) mice but was unchanged
inAngII-treatedTGF-β1-deﬁcientmice[10].Wehavefound
that Ang II stimulated cardiac remodeling, including cardiac
hypertrophy and left ventricular dysfunction, along with
increased expression of TGF-β1 in WT mice. We have also
found that not only WT mice but also gene-engineered
mice such as mice with gene disruption of endothelial nitric
oxide synthase (eNOS), androgen receptor, and heparin
cofactor II manifested acceleration of Ang II-induced cardiac
remodeling with increased expression of TGF-β1[ 37, 38, 41,
42]( Figure 2).
3.3. Possible Link between TGF-β1a n dH y p e r t e n s i o n . Hyper-
tension is a major cause of the development of cardio-
vascular events and causes crucial organ damage such as
renal sclerosis, stroke, and coronary heart disease. While
environmental and lifestyle-related problems including lack
of exercise, obesity, and excessive salt intake contribute to
the increased incidence of hypertension, approximately 50%
of causes of hypertension are thought to have a genetic
background [18]. Recent studies have been suggested that
there is a link between increased levels of circulating TGF-
β1 and hypertension [9]. It has been shown that emilin-
1, an extracellular matrix protein that is associated with
microﬁbrils of the elastic matrix in the aortic media,
modulates TGF-β1 availability and is involved in regulation
of arterial diameter [43]. Gene disruption of emilin-1 results
in increased conversion of pro-TGF-β1t ot h em a t u r ef o r m
and a subsequent increase in TGF-β1 signaling. The accel-
erated TGF-β1 signaling pathway results in a reduction in
arterial lumen diameter with a resultant increase in vascular
resistance and hypertension [43]. A possible mechanism
is that excessive levels of active TGF-β1 cause premature
cytostasis of VSMCs and subsequently suppress arterial wall
expansion. On the other hand, a study using mice has
indicated the possibility that reduced arterial diameter is a
secondary consequence of vascular remodeling [44]. These
accelerated TGF-β1 activation-induced aberrant phenotypes
concerning arterial remodeling and elevated blood pressure
were abolished by disruption of the TGF-β1g e n ei nm i c e
[10].
3.4. TGF-β as a Predictive Biomarker for Cardiovascular Dis-
eases. Previous studies have shown that several components
of TGF-β superfamily signaling pathways have signiﬁcance
as prognostic markers for CVD. For instance, in patients
with coronary artery disease, increased serum levels of TGF-
β1 are signiﬁcantly associated with extended survival with
reduced incidence of coronary events and interventions
[45]. In contrast, after angioplasty, there is a greater risk
of development of restenosis in patients that have higher
levels of TGF-β1 in their blood 15min, 24h, and 2 weeks
after the procedure has been performed [46], suggesting that
these patients would beneﬁt from additional interventions
to prevent restenosis. Further examinations are needed to
clarify the signiﬁcance of serum level of TGF-β1a sa
biomarker of cardiovascular diseases.
4. TGF-β1 andProgressionof Renal Diseases
TGF-β1 is known to induce progression of experimental
renal disease [47]. Suthanthiran et al. demonstrated that
serumTGF-β1proteinlevelswerepositivelyandsigniﬁcantly
associated with plasma renin activity along with elevated
systolic and diastolic blood pressure and were predictive of
microalbuminuria in African Americans [15]. Connective
tissue growth factor (CTGF) expression is stimulated by all
TGF-β isoforms and is abundant in glomerulosclerosis and
other ﬁbrotic disorders [48]. CTGF has been suggested to
mediate proﬁbrotic eﬀects of TGF-β1 and to facilitate inter-
action of TGF-β1 with its receptor [48]. In addition, TGF-β1
is a cytokine known to participate in severalprocesses related
tothedevelopmentofchronickidneydisease(CKD),includ-
ing tubular degeneration [49]. The major pathogenesis has4 Cardiology Research and Practice
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Figure 2: Cardiorenal immunohistochemistry of TGF-β1. TGF-β1-stained spots are observed in the myocardium (upper panels) and
coronary artery (middle panels) in Ang II-infused wild-type mice (upper and middle panels). Macroscopic renal injury and TGF-β1-stained
renal glomerulus are found in Ang II-infused mice, especially eNOS−/− mice (lower panels). Pitavastatin treatment attenuates cardiorenal
TGF-β1 expression in Ang II-infused mice. Modiﬁed from the article by Yagi et al. [37].
been thought to be apoptosis and epithelial-to-mesenchymal
transition of tubule epithelial cells, which is involved in
the ﬁbrotic healing process of the interstitial compartment
[49]. On the other hand, in vivo blockade of TGF-β action
has been shown to reduce CKD-associated tubular damage.
Proliferation of injured and hyperplastic podocytes with
increased TGF-β1 expression has been found in several types
of glomerulonephritis [50]; however, pathophysiological
roles of TGF-β1 in podocyte growth and development of
glomerulosclerosis have not been fully elucidated. Since
TGF-β activates Smads, Ras/extracellular signal-regulated
kinase (ERK) and phosphatidyl inositol-3-kinase (PI3K)
pathways in podocytes [50], enhancement of the TGF-
β/Smad signaling pathway by hyperplastic podocytes has
beenthoughttoleadtomesangialcellmatrixoverproduction
and eventually to podocyte apoptosis and/or detachment,
culminating in the development of glomerulosclerosis.
In addition to glomerulonephritis, autosomal dominant
polycystic kidney disease (ADPKD), a common inherited
renal disease with multiple cysts and interstitial ﬁbrosis
in the kidneys, has been noted as an important cause of
chronic renal failure. Interestingly, Hassane showed that
activation of the TGF-β-Smad signaling pathway is involved
in the progression of ADPKD with increased mRNA levels
of TGF-β target genes, such as ﬁbronectin, collagen type I,
plasminogen activator inhibitor 1 (PAI-1), and MMP-2 [51].
In experimental animal studies, we have found accel-
erated cardiac remodeling with activation of the TGF-β1-
Smad 2/3 signaling pathway in Ang II-induced eNOS+/+
and eNOS−/− mice [37]. High-dose Ang II stimulation also
markedly increased mortality rate with oliguria in eNOS−/−
mice but not in eNOS+/+ mice. In pathological studies,
we have found that pitavastatin treatment attenuates the
enhanced TGF-β1 expression in glomeruli and reduced
the high mortality rate in Ang II-treated eNOS−/− mice
(Figure 2)[ 37]. Taken together, these results indicate that
activation of the TGF-β1-Smad 2/3 signaling pathway is
closely involved in the development of cardiorenal disorders.
5. TGF-β1an dM et abo l icS yn d r o m e
Metabolic syndrome is mostly characterized as visceral fat
obesity with multiple cardiovascular risk factors, including
elevated blood pressure, hyperglycemia, and dyslipidemia.
Therefore, an understanding of the molecular mechanism by
which visceral obesity is promoted is essential for preventing
cardiovascular events in individuals with MetS. In humans,
there is a variant of TGF-β1, commonly known as Pro 10,
that results from substitution of leucine at codon 10 with
proline. This variant has been found in Swedish men and has
been found to cause a 4% increase in BMI, 6% increase in
waist circumference, and a 24% increase in fasting insulin
[52]. Although it has not been determined how the Pro
10 variant form of the TGF-β1 protein is linked to visceral
adiposity and elevated levels of circulating insulin, there is a
possibility that TGF-β1 is involved in the insulin resistance
with obesity. Since macrophage inﬁltration into adipose
tissue causes insulin resistance [53, 54] and since coculture
experiments with human adipocytes and macrophages have
shown that downstream eﬀectors of TGF-β such as PAI-
1, collagen VI, and phosphorylated Smad were increasedCardiology Research and Practice 5
in both macrophages and adipocytes [55], TGF-β has the
potential for increasing insulin resistance. In experimental
animal studies, Samad et al. reported enhancement of
gene and protein expression of TGF-β1 in two strains of
genetically obese mice (ob/ob and db/db) compared with
t h a ti nl e a nm i c e[ 56] and Raju et al. showed that an
obese state increases levels of TGF-β1b u tn o tT G F - β2
in platelets of Zucker rats, recognized as an experimental
model of MetS [57]. Moreover, Sciarretta et al. showed
that serum levels of inﬂammatory markers, including C-
reactive protein, tumor necrosis factor-alpha and TGF-β,i n
hypertensive patients with MetS were signiﬁcantly higher
than those in patients without MetS [16]. Interestingly,
Herder et al. showed that elevated serum concentrations
of TGF-β1 are associated with incident type 2 diabetes
and that the association remained stable in multivariate
analyses taking into account demographic, anthropometric,
metabolic, and lifestyle factors [58]. However, the molecular
pathogenesis between increased serum levels of TGF-β1
and MetS or type 2 diabetes has not been fully eluci-
dated, and further investigations are needed to clarify this
issue.
Since hypertriglycemia is one of the criteria for diagnosis
of MetS, treatment with ﬁbrates for dyslipidemia is thought
to reduce the development of MetS leading to an increase
in cardiovascular events. Nakano et al. demonstrated that
bezaﬁbrate directly inhibits hepatic ﬁbrogenic response
induced by TGF-β1 in vitro. Therefore, the use of bezaﬁbrate
has a possibility to be a new therapeutic strategy against
nonalcoholic steatohepatitis, hepatic ﬁbrosis, and CVD via
attenuation of TGF-β1p r o d u c t i o n[ 59]. Although consider-
ation should be given to monitoring serum creatinine levels,
treatment with fenoﬁbrate, bezaﬁbrate, and gemﬁbrozil, but
not treatment with cloﬁbrate, in patients with elevated
triglycerides and low HDL cholesterol resulted in a lower
incidence of CV events without unfavorable eﬀects on
atherogenic mortality [60–63].
6.Pharmacological Manipulationof TGF-β1
Possible links between the TGF-β1 signaling pathway and
CVD, CKD, and MetS have been noted as mentioned above.
Therefore, modulation of the TGF-β1 pathway by target-
designed molecules or existing pharmacological agents
might be available therapeutic approach in aberrant expres-
sion or signaling activities of TGF-β1-related disorders.
6.1.ManipulationoftheTGF-β1SignalingPathwaybySpeciﬁc
Inhibitors. Several new properties have been proposed as
speciﬁc modulators of the TGF-β signaling pathway. The
secreted exoplasmic domain of the TGF-β type II recep-
tor (TβRII) inhibits the biological eﬀects of TGF-β1 in
vitro [64]. Smith et al. demonstrated that TGF-β signaling
accelerates negative remodeling with adventitial ﬁbrosis and
neointima formation in an arterial balloon injury model
and that this TGF-β-mediated eﬀect was inhibited by a
soluble TGF-β receptor II (TβRII) after vascular injury
[65]. Kingston et al. performed a randomized trial using
a recombinant adenovirus expressing a secreted form of
TβRII to test the hypothesis that localized inhibition of
TGF-β1 inhibits luminal loss after angioplasty, and they
demonstrated that adenovirus-mediated gene transfer of
TβRII attenuates vessel stenosis after angioplasty through
prevention of constrictive remodeling [66]. Furthermore,
small-molecule-speciﬁcinhibitorsofTGF-β1receptorkinase
have been targeted for cancer treatment and experimental
investigationsforthekidney[67],liver[68],andlungﬁbrosis
[69].
6.2. Manipulation of the TGF-β1 Signaling Pathway by
Currently Available Agents. Several currently available agents
have been shown to act on the TGF-β1 signaling path-
way. Redondo et al. demonstrated that TGF-β1p l a y sa n
important role in aspirin-mediated inhibition of cell pro-
liferation via inhibition of VSMC proliferation [70]. They
also reported that pioglitazone, a synthetic PPAR-γ agonist,
subsequently increased the nuclear recruitment of phos-
phorylated Smad2 via TGF-β1 activation leading to VSMC
apoptosis [71]. Statins, HMGCoA reductase inhibitors, have
been established as eﬃcient agents for reducing coronary
plaque instability and cardiovascular death with pleiotropic
eﬀects as well as amelioration of aberrant lipid proﬁles.
Moreover, statins have also been shown to be involved
in expression of TGF-β1 signaling pathways [37, 41, 72,
73]. Porreca et al. showed that pravastatin administration
was associated with increased plasma levels of TGF-β1
in atherosclerotic patients while increasing both protein
synthesis and secretion of TGF-β1i np l a q u em o n o c y t e s ,a n d
they postulated that activated TGF-β1 signaling pathways
lead to stabilization of coronary plaque through anti-
inﬂammatory actions [72]. Interestingly, we and others have
demonstrated that strong statins, including pitavastatin and
atorvastatin, reduced tissue expression levels of cardiore-
nal TGF-β1 leading to attenuation of cell proliferation,
hypertrophic changes, and ﬁbrotic alterations [37, 41, 73].
Therefore, the detailed mechanism of TGF-β1m o d u l a t i o n
by statins remains a matter of debate. In addition, inhibitory
eﬀects of ACE inhibitors and Rho kinase inhibitors on
the TGF-β1 signaling pathway have been reported [74–
76].
Takentogether,theresultsindicatethatanunderstanding
of the organ-speciﬁc pathological role of TGF-β1 and appro-
priate manipulation of TGF-β1 expression and activation
should be considered for prevention of cardiorenal diseases.
7. Conclusions
An understanding of the complexities of the interplay
between the TGF-β1 signaling pathway and the development
of CVD, CKD, and MetS with insulin resistance are matters
of great importance (Figure 3). Based on accumulating
evidence concerning TGF-β1 signaling pathway and human
diseases, appropriate modulation of the biological actions of
TGF-β1 might be a valuable therapeutic approach in patients
with the above-described pathological conditions.6 Cardiology Research and Practice
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Figure 3: Accelerated activation of the TGF-β1 signaling pathway causes CKD, MetS, and CVD. Since TGF-β1 is a common target molecule
and interactive regulator in those pathological conditions, manipulation of the TGF-β1 signaling pathway may be a useful approach for
amelioration of mortality and morbidity in individuals with cardiovascular risk factors.
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